Objective: The study purpose was to examine vision-specific and overall health-related quality of life (QOL) at baseline in Idiopathic Intracranial Hypertension Treatment Trial patients who were newly diagnosed and had mild visual loss. We also sought to determine the associations between vision-specific QOL scores and visual symptoms, visual function, pain, headache-related disability, and obesity.
Idiopathic intracranial hypertension (IIH) is characterized by an elevation of intracranial pressure of uncertain etiology. Once termed "benign intracranial hypertension," case series subsequently showed that some patients may have devastating long-term visual consequences, emphasizing that outcomes of this condition may not always be favorable. 1 Other frequently associated symptoms, including headache, pulse synchronous tinnitus, back and neck pain, and photophobia, also may affect quality of life (QOL). 2 Initial investigations showed reduced QOL in women with IIH 3, 4 and have generated a need for better characterization of IIH-associated morbidity. Assessment of QOL yields a measure for evaluating treatment options.
Previous studies examined QOL in IIH. A retrospective cross-sectional analysis of patients with IIH demonstrated poor overall health-related QOL, measured by the 36-Item Short Form Health Survey (SF-36), when compared with obese and normal weight controls. Furthermore, patients with IIH had increased depression and fatigue. 3 A prospective controlled study of women within 6 months of IIH diagnosis showed decreased QOL, as measured by the SF-36 and the 25-Item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), relative to other neuro-ophthalmic conditions. 4 The IIH Treatment Trial (IIHTT) is the first study to prospectively assess QOL of patients with mild visual loss at the time of diagnosis. The purpose of this paper is to report vision-specific and overall health-related QOL at baseline in IIHTT participants. We also sought to determine associations between vision-specific and overall QOL scores and visual function, symptoms, headache-related disability, and obesity in this cohort.
METHODS Patients. This study was a cross-sectional evaluation of baseline QOL characteristics of participants with IIH and mild visual loss enrolled in the IIHTT, a randomized, double-masked, placebo-controlled trial of acetazolamide. All participants received a low-sodium, weight-reduction diet. To be eligible for the study, participants satisfied the Modified Dandy Criteria for IIH 5 and had baseline computerized automated perimetric mean deviation (PMD) between 22 and 27 dB in the worst affected eye on a 24-2 SITA standard test (Humphrey; Carl Zeiss Meditec, Inc., Dublin, CA). All participants were enrolled within 4 weeks of IIH diagnosis. At the screening visit, the site coordinator explained the Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) Web site and opened an account to give the participant the option of completing the QOL assessments and other self-reported questionnaires online. Study team members took a complete medical history at each participant's screening visit and reviewed it at the baseline visit. They also collected baseline self-reported change in weight over the previous 6 months, weight, standing height, and body mass index (BMI) data.
Other visual function testing. A certified technician measured high-contrast visual acuity using retroilluminated Early Treatment Diabetic Retinopathy Study (ETDRS) charts (Lighthouse International Low Vision Products, New York, NY). The technician also tested low-contrast letter acuity using retroilluminated, low-contrast Sloan letter charts (Precision Vision, La Salle, IL) at 2.5% and 1.25% contrast levels. Study team members performed an ocular examination, pupillary testing, and direct and indirect ophthalmoscopic evaluations at the screening and baseline visits. The site investigator and the Photographic Reading Center graded papilledema for each eye using the Frisén Scale. 6, 7 QOL assessments. We administered QOL questionnaires at the baseline visit. Participants completed the questionnaires on the NORDIC Web site up to 1 week before baseline, or completed the questionnaires during the baseline visit. Visionspecific QOL was assessed with the NEI-VFQ-25. 8, 9 This selfadministered scale includes 25 questions with response gradings that use a Likert scale. Assessment also included administering the more recently designed (Raphael 2006 ) 10-Item NeuroOphthalmic Supplement to the NEI-VFQ-25. 9 The SF-36 measured overall health-related QOL. 10 Each patient also completed the 6-item Headache Impact Test (HIT-6) questionnaire 11 to evaluate headache disability and the Berlin Sleep Apnea Questionnaire to discern the possibility of underlying sleep apnea, which would exclude the patient from participating. The present report includes only the baseline data from the IIHTT. One participant's baseline NEI-VFQ-25, Neuro-Ophthalmic Supplement, and SF-36 were unavailable/ incomplete, as was the Neuro-Ophthalmic Supplement for 2 other participants.
Standard protocol approvals, registrations, and patient consents. We conducted this study in accordance with the Declaration of Helsinki. The institutional review board at each site approved this study, and all participants provided written informed consent.
Statistical analysis. Statistical analyses used R 3.0.3 (The R Foundation for Statistical Computing, http://www.r-project.org). Linear regression models examined the associations between QOL scores (NEI-VFQ-25, Neuro-Ophthalmic Supplement, and SF-36 Physical and Mental Component Summaries) and, separately, each of 35 participant characteristics: age, race, sex, BMI, years of education, current and longest class of occupation, years in current and longest class of occupation, marital status, visual acuity in each eye, PMD in each eye, Frisén papilledema grade in each eye, CSF opening pressure, symptoms of back pain, neck pain, binocular diplopia, cognitive dysfunction, dizziness/vertigo, nocturia, photophobia, radicular pain, pulsatile tinnitus, nonpulsatile tinnitus, subjective visual change for the worse, constant visual loss, transient visual obscurations, history of migraine, amblyopia in either eye, and recent weight gain, and HIT-6 score and high-risk Berlin questionnaire score. Additional univariate models evaluated each subscale of the 4 QOL scales as outcome variables. Robust (sandwich) variance estimates determined confidence intervals (CIs) and p values due to heteroscedasticity (i.e., nonconstant variance of the residuals from the fitted regression model). 12 The investigators considered all variables in the univariate analyses for inclusion in a multiple linear regression model, and they used an all subsets approach to select models for consideration based on Mallows C p 13 and the Bayesian information criterion. 14 
RESULTS
Demographics. One hundred sixty-one women and 4 men met all eligibility criteria and enrolled in the trial. [15] [16] [17] Table 1 lists participant characteristics and corresponding characteristics of cohorts from other studies. The age range was 18 to 52 years. Most participants (65%) self-identified as white/Caucasian while 25% were African American, 2% were Native American, and 8% were of other races or did not report their race; also, 13% were Hispanic/Latino. A BMI .30 kg/m 2 , indicating obesity, was present in 88% of patients. Symptoms. The most frequent symptoms at study entry were headache in 84% and transient visual obscurations in 68%. Patients also commonly reported tinnitus, both pulsatile (52%) and nonpulsatile (23%), back pain (52%), dizziness (51%), photophobia (48%), neck pain (42%), cognitive dysfunction (21%), and radicular pain (19%). Diplopia was reported in 18%; however, only 3% had an esotropia or sixth nerve palsy documented on the examination.
Headache severity on entry was 6.3 6 1.9 on a 0 to 10 visual analog scale; only 5.4% reported headache severity of 10/10 on this scale. The majority of patients (51%) indicated that they experienced headache on a daily basis. A substantial proportion (41%) of patients reported a history of migraine. The HIT-6 headache disability score averaged 59.7 6 9.0 and ranged from 36 to 78 (of a possible 78 as the maximum disability score).
Regarding symptoms, higher HIT-6 score, indicating a greater headache burden, was associated with a lower (worse) NEI-VFQ-25 composite score (figure, table 2). Transient visual obscurations, subjective constant visual loss, dizziness/vertigo, photophobia, neck pain, radicular pain, self-reported cognitive dysfunction, and high risk score on the Berlin Sleep Apnea Questionnaire were significantly associated with a lower NEI-VFQ-25 composite score (table 2) . However, there was no significant association between NEI-VFQ-25 composite score and pulsatile tinnitus, nonpulsatile tinnitus, or back pain.
Visual acuity and visual fields. The average PMD in the study eye (worse eye) was 23.5 6 1.1 dB. In the nonstudy eye, the PMD was 22.3 6 1.1 dB. The average visual acuity in the study eye was 86.3 6 5.5 letters identified correctly on the ETDRS chart; in the nonstudy eye, the average was 87.3 6 5.5 ETDRS letters. There was a significant association of PMD in each eye with NEI-VFQ-25 composite score ( There were significant associations between the Neuro-Ophthalmic Supplement and self-reported cognitive dysfunction, dizziness/vertigo, neck pain, photophobia, radicular pain, years of education, Comparisons with disease-free controls. Study findings indicated a reduction in mean vision-specific QOL (NEI-VFQ-25 composite and Neuro-Ophthalmic Supplement) scores, as well as mean overall QOL (SF-36) scores (table e-3), compared with those reported for disease-free controls. 4, 9 In addition, the average NEI-VFQ-25 composite score and NeuroOphthalmic Supplement score were worse than the scores reported for individuals with multiple sclerosis (MS) and optic neuritis. 9 Multiple regression models for the NEI-VFQ-25 composite score. A multiple linear regression model with Mallows C p closest to the number of parameters found that lower PMD in the best eye, worse visual acuity in the worst eye, higher HIT-6 score, presence of neck pain, presence of transient visual obscurations, and presence of binocular diplopia were associated with reduced vision-specific QOL as measured by the NEI-VFQ-25 composite score (table 3) . The model with the minimum Bayesian information criterion contained only neck pain, HIT-6 score, transient visual obscurations, and visual acuity in the worst eye. Other similar models variably contained PMD in the best eye or diplopia. DISCUSSION Study results demonstrate that IIH affects both vision-specific and overall QOL. Compared with published controls and norms, these reductions are substantial even at diagnosis and with only mild visual loss. Reductions in vision-specific QOL measured by the NEI-VFQ-25 and Neuro-Ophthalmic Supplement were comparable to those for patients with MS (mean NEI-VFQ-25 composite score 87.7) and for patients with MS who had a history of acute optic neuritis (mean NEI-VFQ-25 composite score 82.4). 9, 18 Visual symptoms, headache, and sleep apnea risk, but not BMI, were associated with reduced QOL in our cohort.
This study expands on previous QOL studies showing reduced QOL in individuals with IIH shortly after diagnosis and in subjects with mild visual loss. It also expands on previous QOL studies 3, 4 that captured individuals within the first year of IIH diagnosis 4 and those who had it chronically. 3 Our study is unique in that it demonstrates QOL reduction before medical treatment, suggesting that the effects of intracranial hypertension, and not medication side effects, are the primary cause of symptoms resulting in poor QOL among patients with IIH.
Despite the mild visual loss in IIHTT participants, item scores on the Neuro-Ophthalmic Supplement were reduced in the areas of blurred vision, eyes feeling fatigued, and the patient feeling that the "2 eyes [were] seeing differently." On the NEI-VFQ-25, the ocular pain and distance driving subscale scores were prominently affected. Transient visual obscurations, neck pain, and binocular diplopia were independently associated with a lower NEI-VFQ-25 composite score. While only 3% of patients had an esotropia and a sixth nerve palsy documented on examination, 18% complained of diplopia and eyes not working well together. These symptoms, along with headache, apparently are important correlates of visual QOL, and because they were associated with reduced SF-36 scores, they also seem to affect general QOL. The PMD in the best eye and the visual acuity in the worst eye also contribute to worsening of visual QOL. Because humans are foveate, patients are more aware of their central visual acuity, and many disorders affecting the peripheral vision do not become apparent until central acuity is affected. Then, patients will promptly notice acuity in the worst eye, just as in other conditions that affect central visual acuity (e.g., optic neuritis, central serous retinopathy). However, patients will not notice visual field loss until the loss is more severe and bilateral; the visual field, therefore, in the best eye is more important than that in the worst eye. This may explain why the worst eye's visual acuity, but the best eye's PMD, is more important than the contralateral eye in each case.
Headache severity, as measured by the HIT-6, was associated with the NEI-VFQ-25 composite score, the Neuro-Ophthalmic Supplement score, and scores on SF-36. One might expect that headache alone would worsen QOL; however, others have reported that individuals with episodic migraine had QOL scores that were similar to those in the general population. 19 This may be because most migraine headaches are intermittent and headache in IIH is usually chronic. Chronic migraine and chronic headaches associated with medication overuse are associated with worse QOL both directly and indirectly by worsening depression. 20 As is the case in patients with chronic migraine, 21, 22 headache seems to be a direct significant contributor to lower QOL in patients with IIH. In fact, the HIT-6 score was associated with every SF-36 subscale. Headache appears to affect even visual QOL. However, when we controlled for HIT-6 score in our multiple regression model (table 3) , other factors besides pain accounted for decreases in QOL including visual acuity, PMD, diplopia, and transient visual obscurations. In addition, reviewing the univariate linear models for the NEI-VFQ-25 subscales (table e-1), both HIT-6 score and transient visual obscurations were most highly associated with QOL. In fact, the presence of transient visual obscurations was associated with nearly all aspects of visual QOL. Pain alone is not the sole determinant of reduced visual QOL in IIH.
Obesity is associated with lower QOL scores. [23] [24] [25] [26] [27] Patients with IIH, however, compared with obese controls, 3 showed lower scores on the SF-36. The obese controls in that study showed a higher incidence of depression and anxiety than individuals of normal weight. In this study, the presence of obesity was not associated with worse QOL in patients with IIH. Sleep apnea, however, may be an important obesity-related comorbidity leading to reduced QOL among patients with IIH as one would expect that nonrestorative sleep may worsen QOL. We investigated risk of sleep apnea in patients with IIH who did not have a history of sleep apnea. A high risk score on the Berlin Sleep Apnea Questionnaire was associated with lower scores on the NEI-VFQ-25, the SF-36 Physical and Mental Component Summaries, and the general health subscale on the SF-36 (tables 2 and e-1). Furthermore, several studies have shown reduced QOL among patients with obstructive sleep apnea. 28, 29 In addition, QOL in patients with sleep apnea is associated with their daytime sleepiness. 30 Fatigue is a common complaint in IIH. 3 While we did not directly assess fatigue, we observed a reduced SF-36 vitality subscale score compared with national normative data, and a high-risk Berlin Sleep Apnea score correlated with worse SF-36 vitality score. Therapies that address sleep apnea, fatigue, or both may be helpful in reducing the morbidity associated with IIH.
Several series regarding patients with IIH have reported cognitive dysfunction associated with a lower NEI-VFQ-25 composite score and NeuroOphthalmic Supplement score. 31 It may be that symptoms of cognitive dysfunction also contribute to a lower QOL.
A limitation of this study is the absence of weightmatched controls. However, our findings parallel other controlled QOL studies 3, 4 in which QOL scores in controls were similar to published national norms.
9, 10 We did not assess participants for depression or directly investigate fatigue. These may be important determinants of QOL in IIH. Another limitation is that individuals completed the questionnaires at various times after the lumbar puncture required for IIH diagnosis. The lumbar puncture could conceivably confound some of the QOL scales. However, since study participants completed questionnaires about 1 week after the lumbar puncture, it is less likely to be an important factor.
IIH markedly affects QOL. Visual loss, headache, neck pain, transient visual obscurations, and binocular diplopia are all independently associated with poorer QOL in IIH with mild visual loss. Visionrelated QOL in IIH is similar to that measured in other chronic neurologic disorders such as MS. IIH appears to affect QOL even at the time of diagnosis, and aggressively reducing the increased intracranial pressure may improve QOL over time. Further studies and treatments should address factors most affecting QOL; such treatments may augment the beneficial effects of weight reduction and pharmacologic therapies. Reduced QOL is a major morbidity of IIH and appears largely related to symptoms of increased intracranial pressure. Acetazolamide may improve the QOL of patients with IIH and thus may be useful, even in patients who do not appear to be at risk of substantial visual loss. 15 
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